[What perspectives for cognitive remediation in schizophrenia?].
Cognitive deficits are routinely evident in schizophrenia, and are of sufficient magnitude to influence functional outcomes in work, social functioning and illness management. Cognitive remediation is an evidenced-based non-pharmacological treatment for the neurocognitive deficits seen in schizophrenia. Narrowly defined, cognitive remediation is a set of cognitive drills or compensatory interventions designed to enhance cognitive functioning, but from the vantage of the psychiatric rehabilitation field, cognitive remediation is a therapy which engages the patient in learning activities that enhance the neurocognitive skills relevant to their chosen recovery goals. Cognitive remediation programs vary in the extent to which they reflect these narrow or broader perspectives but a metaanalytic study reports moderate range effect sizes on cognitive test performance, and daily functioning. Reciprocal interactions between baseline ability level, the type of instructional techniques used, and motivation provide some explanatory power for the heterogeneity in patient response to cognitive remediation. Recent studies indicate that intrinsic motivation mediates the relationship between neurocognition and functional outcomes. Results of these studies suggest that intrinsic motivation should be a viable treatment target in cognitive remediation intervention. In this perspective, NEAR (Neuropsychological Educational Approach to Remediation) program was created to enhance intrinsic motivation by employing more engaging and interesting software packages for cognitive practice, involving consumers in choosing the focus of training and having the NEAR leader serve as a coach to engage the consumers in active guidance of their own treatment program.
Pôle universitaire de psychiatrie, hôpital Sainte-Marguerite, 13274 Marseille cedex 09, France. nadia.correard@ap-hm.fr
N
N
Correard
P
P
Mazzola-Pomietto
S-N
SN
Elissalde
N
N
Viglianese-Salmon
E
E
Fakra
J-M
JM
Azorin
D014150:Antipsychotic Agents / Q000627:therapeutic use; D003072:Cognition Disorders / Q000523:psychology / Q000628:therapy*; D015928:Cognitive Behavioral Therapy; D003131:Combined Modality Therapy; D003194:Computer-Assisted Instruction; D019317:Evidence-Based Medicine; D006801:Humans; D009042:Motivation; D010353:Patient Education as Topic; D011613:Psychotherapy; D012559:Schizophrenia / Q000628:therapy*; D012565:Schizophrenic Psychology; D012648:Self Care / Q000523:psychology; D012917:Social Adjustment; D012984:Software; D016896:Treatment Outcome
D014150:Antipsychotic Agents